Metabolic disease drug discovery - "Hitting the target" is easier said than done

Cell Metabolism

Volumn 15, Issue 1, 2012, Pages 19-24

  Moller, David E ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HORMONE RECEPTOR STIMULATING AGENT; LINAGLIPTIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG;

DRUG DEVELOPMENT; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; HUMAN; METABOLIC DISORDER; PRIORITY JOURNAL; REVIEW;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG DISCOVERY; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC DISEASES; RECEPTORS, GLUCAGON;

EID: 84855440149     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2011.10.012     Document Type: Review

References (50)

1. B. Ahrén, E. Simonsson, H. Larsson, M. Landin-Olsson, H. Torgeirsson, P.A. Jansson, M. Sandqvist, P. Bvenholm, S. Efendic, and J.W. Eriksson Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes Diabetes Care 25 2002 869 875 (Pubitemid 41094285)
2. American Diabetes Association Standards of medical care in diabetes - 2011 Diabetes Care 34 Suppl 1 2011 S11 S61
3. N. Bristol NIH proposes new drug development centre Lancet 377 2011 705 706
4. R. Brommage, U. Desai, J.P. Revelli, D.B. Donoviel, G.K. Fontenot, C.M. Dacosta, D.D. Smith, L.L. Kirkpatrick, K.J. Coker, and M.S. Donoviel High-throughput screening of mouse knockout lines identifies true lean and obese phenotypes Obesity (Silver Spring) 16 2008 2362 2367
5. S.L. Conarello, Z. Li, J. Ronan, R.S. Roy, L. Zhu, G. Jiang, F. Liu, J. Woods, E. Zycband, and D.E. Moller Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance Proc. Natl. Acad. Sci. USA 100 2003 6825 6830 (Pubitemid 36666664)
6. D.P.V. de Kleijn, F.L. Moll, W.E. Hellings, G. Ozsarlak-Sozer, P. de Bruin, P.A. Doevendans, A. Vink, L.M. Catanzariti, A.H. Schoneveld, and A. Algra Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events Arterioscler. Thromb. Vasc. Biol. 30 2010 612 619
7. C.F. Deacon, M.A. Nauck, M. Toft-Nielsen, L. Pridal, B. Willms, and J.J. Holst Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects Diabetes 44 1995 1126 1131
8. C.F. Deacon, and J.J. Holst Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective Biochem. Biophys. Res. Commun. 294 2002 1 4 (Pubitemid 34687205)
9. K.B. Degn, C.B. Juhl, J. Sturis, G. Jakobsen, B. Brock, V. Chandramouli, J. Rungby, B.R. Landau, and O. Schmitz One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes Diabetes 53 2004 1187 1194 (Pubitemid 38569002)
10. H.-U. Demuth, S.A. Hinke, R.A. Pederson, and C.H. McIntosh Rebuttal to Deacon and Holst: "Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1" versus "Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective" Biochem. Biophys. Res. Commun. 296 2002 229 232
11. D.J. Drucker The biology of incretin hormones Cell Metab. 3 2006 153 165
12. D.J. Drucker, and A.B. Goldfine Cardiovascular safety and diabetes drug development Lancet 377 2011 977 979
13. J. Eng, W.A. Kleinman, L. Singh, G. Singh, and J.P. Raufman Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas J. Biol. Chem. 267 1992 7402 7405
14. M.S. Fineman, T.A. Bicsak, L.Z. Shen, K. Taylor, E. Gaines, A. Varns, D. Kim, and A.D. Baron Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes Diabetes Care 26 2003 2370 2377 (Pubitemid 36993328)
15. Food and Drug Administration (2006). Press Release: "Pfizer Stops all Torcetrapib Clinical Trials in Interest of Patient Safety," December 3, 2006. http://www.FDA.gov.
16. G. Gaich, and D. Moller New mechanisms and translational paradigms B.H. Littman, R. Krishnan, Translational Medicine and Drug Discovery 2011 Cambridge University Press Cambridge, UK 89 108
17. J.R. Greenfield, J.W. Miller, J.M. Keogh, E. Henning, J.H. Satterwhite, G.S. Cameron, B. Astruc, J.P. Mayer, S. Brage, and T.C. See Modulation of blood pressure by central melanocortinergic pathways N. Engl. J. Med. 360 2009 44 52
18. K.B. Hansen, F.K. Knop, J.J. Holst, and T. Vilsbøll Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists Int. J. Clin. Pract. 63 2009 1154 1160
19. C. Harrison Patent watch: the patent cliff steepens Nat. Rev. Drug Discov. 10 2011 12 13
20. B. Hirshberg, and I. Raz Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs Diabetes Care 34 Suppl 2 2011 S101 S106
21. T.J. Hoerger, J.E. Segel, E.W. Gregg, and J.B. Saaddine Is glycemic control improving in U.S. adults? Diabetes Care 31 2008 81 86
22. X. Hu, J.D. Dietz, C. Xia, D.R. Knight, W.T. Loging, A.H. Smith, H. Yuan, D.A. Perry, and J. Keiser Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition Endocrinology 150 2009 2211 2219
23. IMIDIA. (2011). European compined excellence in diabetes research (http://www.imidia.org).
24. International Diabetes Federation (2011). IDF Disease Atlas (http://www.diabetesatlas.org).
25. K.-H. Jeong, and B.K. Yoo The efficacy and safety of liraglutide Int. J. Clin. Pharmacol. 33 2011 740 749
26. I. Kola The state of innovation in drug development Clin. Pharmacol. Ther. 83 2008 227 230
27. B. Kreymann, G. Williams, M.A. Ghatei, and S.R. Bloom Glucagon-like peptide-1 7-36: a physiological incretin in man Lancet 2 1987 1300 1304 (Pubitemid 17156636)
28. G.R. Lankas, B. Leiting, R.S. Roy, G.J. Eiermann, M.G. Beconi, T. Biftu, C.C. Chan, S. Edmondson, W.P. Feeney, and H. He Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9 Diabetes 54 2005 2988 2994 (Pubitemid 41401097)
29. W.R. Lariviere, E.J. Chesler, and J.S. Mogil Transgenic studies of pain and analgesia: mutation or background genotype? J. Pharmacol. Exp. Ther. 297 2001 467 473 (Pubitemid 32377973)
30. H.K. Lee, E.B. Choi, and C.S. Pak The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents Curr. Top. Med. Chem. 9 2009 482 503
31. 2 assay panel J. Biomol. Screen. 16 2011 588 602
32. P. Libby, P.M. Ridker, and G.K. Hansson Progress and challenges in translating the biology of atherosclerosis Nature 473 2011 317 325
33. P.K. Lund, R.H. Goodman, P.C. Dee, and J.F. Habener Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem Proc. Natl. Acad. Sci. USA 79 1982 345 349 (Pubitemid 12137713)
34. M.I. McCarthy Genomics, type 2 diabetes, and obesity N. Engl. J. Med. 363 2010 2339 2350
35. R. Mentlein, B. Gallwitz, and W.E. Schmidt Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum Eur. J. Biochem. 214 1993 829 835 (Pubitemid 23188160)
36. C.-P. Milne Fixing the paradigm for biopharmaceutical R&D: Where to start? Int. J. Biotechnol. 10 2008 404 415
37. C.-P. Milne Can translational medicine bring us out of the R&D wilderness? Personalized Medicine 6 2009 543 553
38. A. Mullard 2010 FDA drug approvals Nat. Rev. Drug Discov. 10 2011 82 85
39. M.A. Nauck, N. Kleine, C. Orskov, J.J. Holst, B. Willms, and W. Creutzfeldt Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients Diabetologia 36 1993 741 744 (Pubitemid 23218642)
40. M.A. Nauck Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications Am. J. Med. 124 1, Suppl 2011 S3 S18
41. F. Pammolli, L. Magazzini, and M. Riccaboni The productivity crisis in pharmaceutical R&D Nat. Rev. Drug Discov. 10 2011 428 438
42. S.M. Paul, D.S. Mytelka, C.T. Dunwiddie, C.C. Persinger, B.H. Munos, S.R. Lindborg, and A.L. Schacht How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
43. R.P. Pauly, H.-U. Demuth, F. Rosche, J. Schmidt, H.A. White, F. Lynn, C.H. McIntosh, and R.A. Pederson Inhibition of dipeptidyl peptidase IV (DP IV) in rat results in improved glucose tolerance Regul. Pept. 64 1996 148
44. E.E. Schadt Molecular networks as sensors and drivers of common human diseases Nature 461 2009 218 223
45. K.W. Sloop, F.S. Willard, M.B. Brenner, J. Ficorilli, K. Valasek, A.D. Showalter, T.B. Farb, J.X. Cao, A.L. Cox, and M.D. Michael Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets Diabetes 59 2010 3099 3107
46. S. Subbarayan, and M. Kipnes Sitagliptin: a review Expert Opin. Pharmacother. 12 2011 1613 1622
47. D.C. Swinney, and J. Anthony How were new medicines discovered? Nat. Rev. Drug Discov. 10 2011 507 519
48. H.C. Gerstein, M.E. Miller, S. Genuth, F. Ismail-Beigi, J.B. Buse, D.C. Goff Jr., J.L. Probstfield, W.C. Cushman, H.N. Ginsberg, J.T. Bigger ACCORD Study Group Long-term effects of intensive glucose lowering on cardiovascular outcomes N. Engl. J. Med. 364 2011 818 828
49. T.J. Wang, M.G. Larson, R.S. Vasan, S. Cheng, E.P. Rhee, E. McCabe, G.D. Lewis, C.S. Fox, P.F. Jacques, and C. Fernandez Metabolite profiles and the risk of developing diabetes Nat. Med. 17 2011 448 453
50. Y. Yang, S.J. Adelstein, and A.I. Kassis Target discovery from data mining approaches Drug Discov. Today 14 2009 147 154